CTRI/2025/07/091371RecruitingPhase 3
A randomized, double blind, placebo controlled parallel arm clinical study to evaluate the efficacy of LN18178 in improving muscle strength, aerobic capacity and body composition in healthy young males.
GENCOR lifestage solutions1 site in 1 country120 target enrollmentStarted: August 4, 2025Last updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- Change in Muscle strength (1-RM leg press)
Study Overview
Brief Summary
The Purpose of the study is to evaluate the efficacy of LN18178 in improving muscle strength, aerobic capacity and body composition in healthy young males. A total of 120 male subjects aged between 36 and 50 years will be included in the study. Assessment of inclusion and exclusion criteria will be done based on clinical and laboratory investigations. The eligible subjects will be randomized as per the computer-generated randomization list. The subjects will be assigned to either LN18178:400 mg or Placebo arm at 1:1 ratio. The subjects will be instructed to take one capsule daily in the morning after breakfast with water for 12 weeks. Apart from primary and secondary outcomes, the study will also record the vital sign and adverse events to evaluate the herbal composition safety and tolerability. The safety assessment of the LN18178 will also include routine laboratory investigations on blood, urine and clinical chemistry at screening and the final visit of the intervention.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Masking
- Participant, Investigator and Outcome Assessor Blinded
Eligibility Criteria
- Ages
- 36.00 Year(s) to 50.00 Year(s) (—)
- Sex
- Male
Inclusion Criteria
- •Untrained healthy male subjects aged between 36 and 50 years with a Body Mass Index (BMI) between 22 and 27 kg/m
- •Willingness to do exercise training program during the course of the study.
- •Subject considered generally healthy as per health history and routine clinical investigations.
- •Ability to understand the risks and benefits of the protocol.
- •Subject should provide written informed consent and agree to be available for regular follow up throughout the study duration.
- •Subjects who are sexually active must agree to use adequate non-hormonal contraception during the study
- •Subjects agree to maintain current diet and activity level.
- •Subject agrees not to start any new therapies for energy boosting supplements or protein supplements or health drinks during the course of the study.
- •Subjects willing to refrain from drinking coffee or caffeinated drinks or beverages during the study.
Exclusion Criteria
- •Subjects who are resistance trained or undergoing resistance training.
- •Subjects with blood pressure more than or equal to 140/90 mmHg, fasting plasma glucose more than 125 mg/dL and abnormal ECG.
- •Subjects underwent treatment for COVID-19 within last 3 months or tested positive during the study will be excluded.
- •Evidence or history of musculoskeletal, respiratory, haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic diseases, malignancies.
- •Subjects diagnosed with sleep apnea or related disorders.
- •Subjects consuming medications that can interfere with muscle mass such as corticosteroids, testosterone replacement or anabolic drugs.
- •History of psychiatric disorder that may impair the ability of subjects to provide written informed consent.
- •Subjects consuming alcohol (more than 3 standard drinks per week) or smokers ( more than 3 cigarettes per day).
- •Subjects under medications including anti-hypertensives, antidepressants, anticholinergics, inhaled beta agonists, anti-hyperlipidemics, psychotropics etc.
- •Subjects using any centrally acting anorectic agents, drugs that inhibit the absorption of nutrients and endocannabinoid neuromodulators during the two weeks prior to enrolment into the study.
- •Subjects who underwent major surgical procedures in last 6 months.
- •Subject with HIV positive or history of any other STDs.
- •Subject has participated in a clinical study within the last 30 days prior to recruitment or concurrently participating in another study.
Outcomes
Primary Outcomes
Change in Muscle strength (1-RM leg press)
Time Frame: Week 0, Week 2, Week 4, Week 8 and Week 12
Secondary Outcomes
- Change in Muscle strength ( 1-RM bench press)(Week 0, Week 2, Week 4, Week 8 and Week 12)
- Change in Muscle endurance (Repetitions to failure for leg press and bench press using 80% 1RM)(Week 0, Week 2, Week 4, Week 8 and Week 12)
- Change in training volume/capacity(Week 0, Week 2, Week 4, Week 8 and Week 12)
- Change in VO2 max testing (graded exercise test while O2 consumption measured)(Week 0 and Week 12)
- Change in Lean body mass (DEXA)(Week 0 and Week 12)
- Change in Rate of Perceived Exertion (RPE) using 6-20 point borg scale for exercise intensity(Week 0, Week 2, Week 4, Week 8 and Week 12)
- Change in subjective rating of Energy, Fatigue, Focus and Confidence using VAS(Week 0, Week 2, Week 4, Week 8 and Week 12)
- Change in subjective feeling of mental acuity, concentration, calmness and quality of sleep using VAS(Week 0, Week 2, Week 4, Week 8 and Week 12)
- Change in Physical Activity Enjoyment Scale-8 (PACES)(Week 0, Week 2, Week 4, Week 8 and Week 12)
- Change in Serum biomarkers (IGF-1 and Myostatin)(Week 0 and Week 12)
Investigators
Dr Ashutosh Mishra
Panacea Hospital and Diabetes Care Organization
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 2
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.ObesityNCT07411378Biophytis164
Recruiting
Phase 2
Safety and efficacy of NMD670 in ambulatory adult patients with Type 3 spinal muscular atrophy (SYNAPSE-SMA)2024-516321-31-00NMD Pharma A/S69
Recruiting
Phase 3
A study to assess the efficacy and safety of Empasiprubart versus IVIg in adults with Multifocal Motor NeuropathyMultifocal Motor Neuropathy2024-516473-72-00Argenx134
Recruiting
Phase 2
LY4268989 in Adults With Moderately to Severely Active Ulcerative ColitisNCT07415044Eli Lilly and Company1,431
Not yet recruiting
Phase 2
Improving Back Muscle Function with a Gentle Stretching Technique in People with Low Back Pain.CTRI/2025/08/092782Ankita Maniyar19